These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1140 related items for PubMed ID: 27635024

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery.
    Knipper S, Tilki D, Mansholt J, Berliner C, Bernreuther C, Steuber T, Maurer T, Graefen M.
    Eur Urol Focus; 2019 Jan; 5(1):50-53. PubMed ID: 30292421
    [Abstract] [Full Text] [Related]

  • 23. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
    Mosayebnia M, Hajimahdi Z, Beiki D, Rezaeianpour M, Hajiramezanali M, Geramifar P, Sabzevari O, Amini M, Hatamabadi D, Shahhosseini S.
    Bioorg Chem; 2020 Jun; 99():103743. PubMed ID: 32217372
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, Kulkarni HR, Lassmann M, Klette I, Eiber M, Schwaiger M, Wester HJ.
    J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
    [Abstract] [Full Text] [Related]

  • 26. [PSMA-radioguided surgery in localized recurrent prostate cancer : Current and future aspects].
    Rauscher I, Eiber M, Jilg CA, Gschwend JE, Maurer T.
    Urologe A; 2017 Jan; 56(1):18-23. PubMed ID: 27885455
    [Abstract] [Full Text] [Related]

  • 27. Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer.
    Rauscher I, Maurer T, Souvatzoglou M, Beer AJ, Vag T, Wirtz M, Weirich G, Wester HJ, Gschwend JE, Schwaiger M, Schottelius M, Eiber M.
    Clin Nucl Med; 2016 Sep; 41(9):e397-402. PubMed ID: 27276206
    [Abstract] [Full Text] [Related]

  • 28. The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients.
    Su HC, Zhu Y, Hu SL, Liu C, Lin GW, Dai B, Zhang YJ, Ye DW.
    Ann Surg Oncol; 2019 Feb; 26(2):653-659. PubMed ID: 30324468
    [Abstract] [Full Text] [Related]

  • 29. Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study.
    de Barros HA, van Oosterom MN, Donswijk ML, Hendrikx JJMA, Vis AN, Maurer T, van Leeuwen FWB, van der Poel HG, van Leeuwen PJ.
    Eur Urol; 2022 Jul; 82(1):97-105. PubMed ID: 35339318
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer.
    Rathke H, Afshar-Oromieh A, Giesel FL, Kremer C, Flechsig P, Haufe S, Mier W, Holland-Letz T, De Bucourt M, Armor T, Babich JW, Haberkorn U, Kratochwil C.
    J Nucl Med; 2018 Sep; 59(9):1373-1379. PubMed ID: 29371410
    [Abstract] [Full Text] [Related]

  • 32. Tc-99m-PSMA imaging allows successful radioguided surgery in recurrent prostate cancer.
    Kratzik C, Dorudi S, Schatzl M, Sinzinger H.
    Hell J Nucl Med; 2018 Sep; 21(3):202-204. PubMed ID: 30411731
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
    Evazalipour M, D'Huyvetter M, Tehrani BS, Abolhassani M, Omidfar K, Abdoli S, Arezumand R, Morovvati H, Lahoutte T, Muyldermans S, Devoogdt N.
    Contrast Media Mol Imaging; 2014 Sep; 9(3):211-20. PubMed ID: 24700748
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. PSMA SPECT/CT with 99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels.
    Schmidkonz C, Goetz TI, Kuwert T, Ritt P, Prante O, Bäuerle T, Goebell P, Cordes M.
    Ann Nucl Med; 2019 Dec; 33(12):891-898. PubMed ID: 31502084
    [Abstract] [Full Text] [Related]

  • 37. Development of (99m)Tc-labeled asymmetric urea derivatives that target prostate-specific membrane antigen for single-photon emission computed tomography imaging.
    Kimura H, Sampei S, Matsuoka D, Harada N, Watanabe H, Arimitsu K, Ono M, Saji H.
    Bioorg Med Chem; 2016 May 15; 24(10):2251-6. PubMed ID: 27073053
    [Abstract] [Full Text] [Related]

  • 38. Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging.
    Kelly J, Amor-Coarasa A, Nikolopoulou A, Kim D, Williams C, Ponnala S, Babich JW.
    Eur J Nucl Med Mol Imaging; 2017 Apr 15; 44(4):647-661. PubMed ID: 27847991
    [Abstract] [Full Text] [Related]

  • 39. [99mTc]Tc-PentixaTec: development, extensive pre-clinical evaluation, and first human experience.
    Konrad M, Rinscheid A, Wienand G, Nittbaur B, Wester HJ, Janzen T, Lapa C, Pfob CH, Schottelius M.
    Eur J Nucl Med Mol Imaging; 2023 Nov 15; 50(13):3937-3948. PubMed ID: 37597009
    [Abstract] [Full Text] [Related]

  • 40. Diagnostic efficacy of [99mTc]Tc-PSMA SPECT/CT for prostate cancer: a meta-analysis.
    Wang Q, Ketteler S, Bagheri S, Ebrahimifard A, Luster M, Librizzi D, Yousefi BH.
    BMC Cancer; 2024 Aug 08; 24(1):982. PubMed ID: 39118101
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 57.